Meeting
2016 ASCO Annual Meeting
Derivation and validation of a prediction scale for response to PD-1 monotherapy.
Authors
Adi Nosrati
University of California San Francisco, San Francisco, CA
Adi Nosrati , Simone M. Goldinger , Katy K. Tsai , Kimberly Loo , Paul Tumeh , Omid Hamid , Alain Patrick Algazi , Mitchell P. Levesque , Reinhard Dummer , Adil Daud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9514)
DOI
10.1200/JCO.2016.34.15_suppl.9514
Abstract #
9514
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane
Poster
2022 ASCO Annual Meeting
A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
First Author: Geoffrey Thomas Gibney
Poster
2019 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
First Author: Emilia Nan Tie